Predicting response and toxicity in patients receiving paclitaxel and Avastin [bevacizumab] for breast cancer: a multicenter genomic, proteomic and pharmacogenomic correlative study.

Trial Profile

Predicting response and toxicity in patients receiving paclitaxel and Avastin [bevacizumab] for breast cancer: a multicenter genomic, proteomic and pharmacogenomic correlative study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2011

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2011 Planned end date changed from 1 Dec 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Actual patient number (11) added as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top